DailyStocks Stock Article Search

https://www.zacks.com/stock/news/2227882/acv-auctions-inc-acva-q4-earnings-on-the-horizon-analysts-insights-on-key-performance-measures?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2227882 Feb 19, 2024 - Evaluate the expected performance of ACV Auctions Inc. (ACVA) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight. 0

https://www.fool.com/investing/2024/02/19/paypal-is-a-magnificent-stock-to-buy-hand-over-fis/?source=iedfolrf0000001 Feb 19, 2024 - Shares are dirt cheap, so value-focused investors might be eyeing the business. 0

https://www.zacks.com/stock/news/2227695/compared-to-estimates-labcorp-lh-q4-earnings-a-look-at-key-metrics-revised?cid=CS-ZC-FT-fundamental_analysis|nfm-2227695 Feb 19, 2024 - Although the revenue and EPS for Labcorp (LH) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. 0

https://seekingalpha.com/article/4671350-palantir-i-believe-healthcare-is-the-key-for-s-and-p-500-inclusion?source=feed Feb 19, 2024 - As Palantir picks up steam in 2024, I believe the AI leader will face compelling healthcare opportunities. Find out why I remain bullish on PLTR stock. 0

https://www.zacks.com/stock/news/2227603/sinclair-sbgi-rises-as-market-takes-a-dip-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2227603 Feb 16, 2024 - In the latest trading session, Sinclair (SBGI) closed at $16.03, marking a +1.2% move from the previous day. 0

https://www.fool.com/investing/2024/02/16/this-company-was-once-a-key-part-of-tilray-brands/?source=iedfolrf0000001 Feb 16, 2024 - Investors have punished Tilray's stock, which is down more than 90% in three years. 0

https://www.zacks.com/stock/news/2227584/royalty-pharma-rprx-q4-earnings-taking-a-look-at-key-metrics-versus-estimates?cid=CS-ZC-FT-fundamental_analysis|nfm-2227584 Feb 16, 2024 - While the top- and bottom-line numbers for Royalty Pharma (RPRX) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. 0

https://www.zacks.com/stock/news/2227586/vulcan-vmc-reports-q4-earnings-what-key-metrics-have-to-say?cid=CS-ZC-FT-fundamental_analysis|nfm-2227586 Feb 16, 2024 - Although the revenue and EPS for Vulcan (VMC) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. 0

https://www.zacks.com/stock/news/2227590/cinemark-cnk-q4-earnings-how-key-metrics-compare-to-wall-street-estimates?cid=CS-ZC-FT-fundamental_analysis|nfm-2227590 Feb 16, 2024 - The headline numbers for Cinemark (CNK) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. 0

https://www.zacks.com/stock/news/2227587/compared-to-estimates-tds-tds-q4-earnings-a-look-at-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm-2227587 Feb 16, 2024 - While the top- and bottom-line numbers for TDS (TDS) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. 0